Recent studies have demonstrated that dysregulated MDH1 is associated with cancer progression, metabolic reprogramming, and therapy resistance in pancreatic cancer (54), breast cancer (55), and lung adenocarcinoma (56). The gene discussed is MDH1; the disease is pancreatic neoplasm.